At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 69 enrolled
Drug / intervention
RPC1063drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
In Brief
A Phase 2 clinical trial evaluating RPC1063 for Crohn's Disease. Completed, enrolled 69 participants across 28 sites in 5 countries.
Detailed Summary
The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesCanada, Hungary, Poland, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartOct 2015
Primary CompletionSep 2019
Study CompletionNov 2019
TodayJul 2026
First PostedAug 24, 2015
Enrollment StartOct 9, 2015
Primary CompletionSep 12, 2019
Study CompletionNov 28, 2019
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.9 years ago
Interventions
RPC1063drug